Currently, there are 41.75M common shares owned by the public and among those 21.84M shares have been available to trade.
The company’s stock has a 5-day price change of -14.05% and -59.10% over the past three months. CARM shares are trading -86.39% year to date (YTD), with the 12-month market performance down to -87.17% lower. It has a 12-month low price of $0.38 and touched a high of $3.16 over the same period. CARM has an average intraday trading volume of 214.67K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -36.45%, -52.05%, and -67.50% respectively.
Institutional ownership of Carisma Therapeutics Inc (NASDAQ: CARM) shares accounts for 11.18% of the company’s 41.75M shares outstanding.
It has a market capitalization of $16.66M and a beta (3y monthly) value of 1.57. The earnings-per-share (ttm) stands at -$1.56. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.97% over the week and 10.80% over the month.
Earnings per share for the fiscal year are expected to increase by 53.13%, and 56.67% over the next financial year.
Looking at the support for the CARM, a number of firms have released research notes about the stock. Robert W. Baird stated their Neutral rating for the stock in a research note on December 12, 2024, with the firm’s price target at $10-$1. BTIG Research was of a view on April 11, 2024 that the stock is Buy, while CapitalOne gave the stock Overweight rating on October 03, 2023, issuing a price target of $10. Evercore ISI on their part issued Outperform rating on July 06, 2023.
